Sherbrooke and Eastern
Please note that the following information was extracted with permission from Investissement QuĂ©becâ€™s website. For more information on the life sciences sector, please please click here.
Pharmaceuticals - R&D
AstraZeneca R&D MontrĂ©al
Â Boehringer Ingelheim (Canada)
Â GSK Biologicals
This biopharmaceutical company is specialized in drug discovery and product development in oncology and endocrine therapy. Its subsidiary, Atrium Innovations, specializes in the development, manufacturing and commercialization of nutritional supplements and health products in more than 35Â countries. Atrium has five production units and more than 575Â employees.
This private company focuses on research into controlling apoptosis in order to kill cancer cells and rescue neurons from cell death. Its leading oncology program is an antisense treatment.
BD Diagnostic GeneOhm
BD Diagnostic GeneOhm is a molecular diagnostic company that ranks among the top developers of fast tests for detecting and identifying a variety of infectious agents and genetic variations.
An affiliate of Becton Dickinson, recently invested $40M to build a manufacturing facility to produce molecular diagnostic test kits for the detection and control of bacterial infections and provide. Construction of the new centre will generate more than 100 new jobs.
Caprion's exclusive proteomic technologies contribute to the discovery of new targets to develop treatments and identify new protein biomarkers that can significantly reduce the risk and improve clinical development activities and decision making during the pharmaceutical research process.
ConjuChem has pioneered a biotechnology that can extend the half-life of a peptide and also reduce a drug's toxicity profile by bioconjugation to albumin. With a priority focus on diabetes, the company is also developing drugs to treat an array of other pathologies such as congestive heart failure and HIV.
DiagnoCure specializes in the development, production and commercialization of diagnostic tests for the early detection of cancer. It has also developed an automated microscopy platform that detects, analyses, compiles and archives data and images.
Labopharm specializes in the development of drugs using controlled-release technologies. It reformulates existing drugs in collaboration with large international pharmaceutical companies.
MethylGene is focused on the discovery, development and commercialization of new therapeutic products for the treatment of cancer and infectious diseases, among others. The company specializes in medicinal, combinational and analytical chemistry and is dedicated to the design, synthesis and optimization of product candidates.
ProMetic Life Sciences
ProMetic has R&D and manufacturing facilities in Canada and the United Kingdom and business development activities in many other countries. The company specializes in two areas: drug development for the treatment of cancer and inflammatory/autoimmune diseases and enabling technologies, a key component in manufacturing biopharmaceutical products.
Thallion Pharmaceuticals develops new treatments for infectious diseases and oncology. Three products are currently in clinical development phases, offering numerous possibilities for various markets as orphan drugs for indications such as glioma and renal cells carcinoma or aiming at more important markets such as melanoma or pancreatic cancer.
Theratechnologies develops therapeutic peptides to treat endocrine and metabolic disorders, such as HIV-related lipodystrophy, cachexia associated with chronic disease, and type II diabetes.
This company, which employs some 400 people, has enjoyed a remarkable growth rate of 300% over the past five years, measured in terms of employees, revenue and capital investments. Algorithme specializes in clinical studies using healthy volunteers; its facilities, equiped for Phase I trials and bioequivalence, include nearlyÂ 300 beds.
As a subsidiary of PharmaNet Development Group, Anapharm is part of North America's biggest independent contract research organization specializing in phase I and phase II trials. So far, the Company has tested more than 300Â products and monitored 100 clinical trials per year for various companies, 50% of them being American, 20% Canadian et 20% European . The Company employs a team of more than 700 research specialists. Anapharm is constantly investing, to expand its bioanalytical laboratory and to add beds for bioequivalence and phase 1 studies.
Laboratoires Charles River
Laboratoires Charles River is one of the world's largest preclinical contract research organizations. The Company currently employs 1,750 employees in MontrĂ©al andÂ Sherbrooke.Â Three expansions are planned for Sherbrooke's site. Upon completion, the site will reach 300,000 sq.ft. and employ more than 1,000 people.
Source : Investissement QuĂ©bec.